IGC Pharma, Inc. financial data

Symbol
IGC on NYSE
Location
Potomac, MD
Fiscal year end
31 March
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 124% % -26%
Quick Ratio 59% % -13%
Debt-to-equity 33% % -1.4%
Return On Assets -73% % 39%
Operating Margin -732% % 7.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 92,868,241 shares 20%
Common Stock, Shares, Outstanding 91,959,112 shares 20%
Entity Public Float $29,724,689 USD 42%
Weighted Average Number of Shares Outstanding, Basic 90,457,910 shares 19%
Weighted Average Number of Shares Outstanding, Diluted 90,457,910 shares 19%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $1,106,000 USD -6.5%
Cost of Revenue $595,000 USD 15%
Research and Development Expense $4,288,000 USD 20%
Operating Income (Loss) $8,094,000 USD 13%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $6,446,000 USD 49%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $6,447,000 USD 49%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,105,000 USD -29%
Accounts Receivable, after Allowance for Credit Loss, Current $41,000 USD -6.8%
Inventory, Net $658,000 USD -56%
Other Assets, Current $130,000 USD -34%
Assets, Current $2,004,000 USD -53%
Property, Plant and Equipment, Net $2,175,000 USD -37%
Operating Lease, Right-of-Use Asset $13,000 USD -92%
Intangible Assets, Net (Excluding Goodwill) $4,879,000 USD 171%
Other Assets, Noncurrent $672,000 USD -2.2%
Assets $9,743,000 USD -6%
Accounts Payable, Current $628,000 USD -18%
Employee-related Liabilities, Current $398,000 USD -62%
Accrued Liabilities, Current $886,000 USD -56%
Liabilities, Current $1,514,000 USD -46%
Operating Lease, Liability, Noncurrent $5,000 USD -86%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $1,651,000 USD -45%
Common Stocks, Including Additional Paid in Capital $135,774,000 USD 5.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax $4,854,000 USD -41%
Retained Earnings (Accumulated Deficit) $122,828,000 USD -4.3%
Stockholders' Equity Attributable to Parent $8,092,000 USD 9.7%
Liabilities and Equity $9,743,000 USD -6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,407,000 USD 20%
Net Cash Provided by (Used in) Financing Activities $851,000 USD -66%
Net Cash Provided by (Used in) Investing Activities $580,000 USD
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 91,959,112 shares 20%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $49,000 USD -92%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,105,000 USD -29%
Interest Paid, Excluding Capitalized Interest, Operating Activities $1,000 USD 0%
Deferred Tax Assets, Valuation Allowance $19,124,000 USD 28%
Deferred Tax Assets, Gross $19,124,000 USD 28%
Operating Lease, Liability $103,000 USD -50%
Depreciation $512,000 USD -11%
Payments to Acquire Property, Plant, and Equipment $8,000 USD -79%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $6,480,000 USD 48%
Property, Plant and Equipment, Gross $3,886,000 USD -36%
Operating Lease, Liability, Current $9,000 USD -93%
Lessee, Operating Lease, Liability, to be Paid, Year Two $10,000 USD -89%
Lessee, Operating Lease, Liability, to be Paid, Year One $96,000 USD -27%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3,000 USD -73%
Lessee, Operating Lease, Liability, to be Paid, Year Three $0 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets $14,000 USD -30%
Depreciation, Depletion and Amortization $141,000 USD -13%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $452,000 USD 12%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%